Latest Upsher-Smith Laboratories Inc. Stories
MAPLE GROVE, Minn., Aug. 1, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc.
MAPLE GROVE, Minn., July 25, 2011 /PRNewswire/ -- In a comparative pharmacokinetic (PK) study, Upsher-Smith Laboratories' USL255, a new, once-daily extended-release formulation of topiramate in development for the management of epilepsy in adults, was shown to be bioequivalent to twice-daily immediate-release topiramate (TopamaxÂ®*) in its extent of absorption.
MAPLE GROVE, Minn., July 18, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc.
MAPLE GROVE, Minn., July 11, 2011 /PRNewswire/ -- Today Upsher-Smith Laboratories, Inc. announced the launch of Trianex(TM) 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment.
MAPLE GROVE, Minn., June 8, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. announced today that it was honored with the prestigious Distribution Industry Award for Notable Achievements in Healthcare (DIANA) presented by the Healthcare Distribution Management Association (HDMA).
MAPLE GROVE, Minn., April 11, 2011 /PRNewswire/ -- Upsher-Smith Laboratories today announced the presentation of data indicating that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, was associated with less fluctuation in topiramate plasma levels compared to immediate-release (IR) topiramate administered twice daily in healthy volunteers.
- totally perplexed and mixed up.